Year-end Sale % OFF 
Abstract
To the Editor: Valgimigli et al1 conducted an interesting prospective study on the effect of tirofiban in poor responders to aspirin, clopidogrel, or both undergoing elective coronary intervention. Although the reasons for recruiting low-risk patients in the study are explained,2 this study cannot be incorporated into commonly encountered advanced cardiac patients. Certain additional details and controversies need to be addressed. I find that the placebo group …
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
